Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. senpet

SenPET SIGNED

Innovative cancer management: First in human senescence imaging

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SenPET project word cloud

Explore the words cloud of the SenPET project. It provides you a very rough idea of what is the project "SenPET" about.

validated    automated    desirable    exceeds    tool    radiosynthesis    physiological    quantification    promotion    gold    progression    cells    setting    larger    collected    medicine    tumors    approval    patients    techniques    accomplished    care    tracer    standard    pet    clinical    termed    senolytics    models    personalized    markers    predictive    distinction    histological    human    clear    proof    team    encouraged    ex    vivo    biomarker    erc    elimination    vitro    convincing    stable    synthesis    protocol    senescence    therapies    gastrointestinal    galactosidase    utmost    first    good    paperwork    detection    data    radiolabeled    patient    compliant    preclinical    tumor    gmp    imagelink    collection    invasive    outcome    chemotherapy    shown    irreversible    biopsies    perform    senpet    protected    marker    plays    cancer    treatment    translate    inducing    staining    patent    szlig    murine    suffering    arrest    manufacturing    senescent    reproducible    industrial    correlated    scope    cellular   

Project "SenPET" data sheet

The following table provides information about the project.

Coordinator		 EBERHARD KARLS UNIVERSITAET TUEBINGEN 

Organization address
address: GESCHWISTER-SCHOLL-PLATZ
city: TUEBINGEN
postcode: 72074
website: www.uni-tuebingen.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Germany [DE]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-04-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EBERHARD KARLS UNIVERSITAET TUEBINGEN DE (TUEBINGEN) coordinator 150˙000.00

Map

 Project objective

The irreversible growth arrest, termed cellular senescence, plays a key role in tumor progression and promotion, as well as in many other physiological processes. It has been shown to be a predictive marker for the long term outcome of cancer treatment and novel therapies aiming at the elimination of senescent cells are under development (i.e. senolytics). Therefore, techniques for the detection of senescence are of utmost importance. However, in the current clinical setting this is only possible with histological staining after collection of invasive biopsies and a tool for non-invasive assessment and quantification of senescence is highly desirable towards improved patient care and personalized medicine.

Within our current ERC project ImageLink we have developed a stable and reproducible synthesis protocol for a novel radiolabeled PET-tracer targeting ß-galactosidase, the “gold-standard” biomarker of senescence. The tracer was validated in several in vitro and in vivo human and murine tumor models. A clear distinction between senescent and non-senescent tumors was possible and the convincing results have encouraged us to translate our preclinical findings into a clinical setting. However, this step exceeds the scope of our current ERC project.

Within the planned project SenPET we will establish an automated radiosynthesis of the tracer that is compliant with good manufacturing practice (GMP) and all necessary paperwork with the authorities for approval of a clinical study will be accomplished. Finally we will perform the first clinical proof of concept study of a senescence PET tracer in 10 patients suffering from gastrointestinal tumors. PET data with our novel tracer will be collected before and after a senescence inducing chemotherapy treatment and correlated with ex vivo markers of senescence. Since our tracer is protected by patent applications, the results of this study will help us to team up with industrial partners to perform larger clinical studies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SENPET" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SENPET" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More  

HEIST (2020)

High-temperature Electrochemical Impedance Spectroscopy Transmission electron microscopy on energy materials

Read More